Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology

Nature Reviews Cancer

Volumn 13, Issue 10, 2013, Pages 685-700

  Hallberg, Bengt ^a   Palmer, Ruth H ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BCL2 RELATED PROTEIN A1; CH 5424802; CLATHRIN HEAVY CHAIN; CRIZOTINIB; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GELATINASE B; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INSULIN RECEPTOR SUBSTRATE 2; JANUS KINASE; LOW DENSITY LIPOPROTEIN RECEPTOR; MICRORNA 16; MICRORNA 29A; MYOSIN HEAVY CHAIN; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 3; PHOSPHOLIPASE C GAMMA; PROTEIN TYROSINE KINASE INHIBITOR; RING FINGER PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR JUNB; TRANSFORMING GROWTH FACTOR BETA; TROPOMYOSIN; UNCLASSIFIED DRUG;

ANAPLASTIC THYROID CANCER; B CELL LYMPHOMA; BREAST CANCER; CAENORHABDITIS ELEGANS; CANCER PATIENT; CANCER RESISTANCE; CARCINOGENESIS; CARCINOGENICITY; CELL GROWTH; CELL SURVIVAL; CELLULAR DISTRIBUTION; CHILDHOOD CANCER; CHROMOSOME 2P; COLON CARCINOMA; DISEASE COURSE; DROSOPHILA MELANOGASTER; ENZYME ACTIVATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FLUORESCENCE IN SITU HYBRIDIZATION; HEART RATE; HUMAN; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LUNG NON SMALL CELL CANCER; NEOPLASM; NERVOUS SYSTEM DEVELOPMENT; NEUROBLASTOMA; NEUROMUSCULAR SYNAPSE; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PLASMA CELL GRANULOMA; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; SURVIVAL; SYNAPSE; TESTOSTERONE BLOOD LEVEL; VISUAL DISORDER; ZEBRA FISH;

EID: 84884549747     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3580     Document Type: Review

References (219)

1. Morris, S. W. et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263, 1281-1284 (1994). The first report of a chromosomal translocation in human cancer involving the ALK locus.
2. Shiota, M. et al. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 9, 1567-1574 (1994).
3. Iwahara, T. et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 14, 439-449 (1997).
4. Kruczynski, A., Delsol, G., Laurent, C., Brousset, P. & Lamant, L. Anaplastic lymphoma kinase as a therapeutic target. Expert Opin. Ther. Targets 16, 1127-1138 (2012).
5. Mosse, Y. P., Wood, A. & Maris, J. M. Inhibition of ALK signaling for cancer therapy. Clin. Cancer Res. 15, 5609-5614 (2009).
6. Palmer, R. H., Vernersson, E., Grabbe, C. & Hallberg, B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem. J. 420, 345-361 (2009).
7. Stoica, G. E. et al. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J. Biol. Chem. 276, 16772-16779 (2001).
8. Stoica, G. E. et al. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J. Biol. Chem. 277, 35990-35998 (2002).
9. Kadomatsu, K. & Muramatsu, T. Midkine and pleiotrophin in neural development and cancer. Cancer Lett. 204, 127-143 (2004).
10. Muramatsu, T. Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J. Biochem. (Tokyo) 132, 359-371 (2002).
11. Perez-Pinera, P., Zhang, W., Chang, Y., Vega, J. A. & Deuel, T. F. Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase beta/zeta signaling pathway: an alternative mechanism of receptor tyrosine kinase activation. J. Biol. Chem. 282, 28683-28690 (2007).
12. Mathivet, T., Mazot, P. & Vigny, M. In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)' Cell. Signal. 19, 2434-2443 (2007).
13. Moog-Lutz, C. et al. Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. J. Biol. Chem. 280, 26039-26048 (2005). The first report of antibodies that are able to both activate and inhibit the activity of the full-length ALK receptor.
14. Motegi, A., Fujimoto, J., Kotani, M., Sakuraba, H. & Yamamoto, T. ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth. J. Cell Sci. 117, 3319-3329 (2004).
15. Mourali, J. et al. Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage. Mol. Cell. Biol. 26, 6209-6222 (2006).
16. US Food and Drug Administration. FDA approves Xalkori with companion diagnostic for a type of late-stage lung cancer. US Food and Drug Administration [online], http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm269856. htm (2011).
17. Christensen, J. G. et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther. 6, 3314-3322 (2007). The initial report of crizotinib as an inhibitor of ALK and MET.
18. Ou, S. H. et al. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, F02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J. Thorac. Oncol. 5, 2044-2046 (2010).
19. Weickhardt, A. J. et al. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer 118, 5302-5309 (2012).
20. Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010). This study reported the first clinical trial results of crizotinib on ALK-positive patients with NSCLC.
21. Seto, T. et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol. 14, 590-598 (2013). A recent report on the first clinical trial results of CH5424802 on ALK-positive patients with NSCLC.
22. Degoutin, J., Brunet-de Carvalho, N., Cifuentes-Diaz, C. & Vigny, M. ALK (anaplastic lymphoma kinase) expression in DRG neurons and its involvement in neuron-Schwann cells interaction. Eur. J. Neurosci. 29, 275-286 (2009).
23. Hurley, S. P., Clary, D. O., Copie, V. & Lefcort, F. Anaplastic lymphoma kinase is dynamically expressed on subsets of motor neurons and in the peripheral nervous system. J. Comp. Neurol. 495, 202-212 (2006).
24. Morris, S. W. et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 14, 2175-2188 (1997).
25. Pulford, K. et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 89, 1394-1404 (1997).
26. Vernersson, E. et al. Characterization of the expression of the ALK receptor tyrosine kinase in mice. Gene Expr. Patterns 6, 448-461 (2006).
27. Yan, X. et al. Cooperative cross-talk between neuroblastoma subtypes confers resistance to anaplastic lymphoma kinase inhibition. Genes Cancer 2, 538-549 (2011).
28. Bilsland, J. G. et al. Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications. Neuropsychopharmacology 33, 685-700 (2008).
29. Lasek, A. W. et al. An evolutionary conserved role for anaplastic lymphoma kinase in behavioral responses to ethanol. PLoS ONE 6, e22636 (2011).
30. Weiss, J. B. et al. Anaplastic lymphoma kinase and leukocyte tyrosine kinase: functions and genetic interactions in learning, memory and adult neurogenesis. Pharmacol. Biochem. Behav. 100, 566-574 (2012).
31. Liao, E. H., Hung, W., Abrams, B. & Zhen, M. An SCF-like ubiquitin ligase complex that controls presynaptic differentiation. Nature 430, 345-350 (2004).
32. Reiner, D. J., Ailion, M., Thomas, J. H. & Meyer, B. J. C. elegans anaplastic lymphoma kinase ortholog SCD-2 controls dauer formation by modulating TGF-' signaling. Curr. Biol. 18, 1101-1109 (2008).
33. Loren, C. E. et al. A crucial role for the anaplastic lymphoma kinase receptor tyrosine kinase in gut development in Drosophila melanogaster. EMBO Rep. 4, 781-786 (2003).
34. Yao, S. et al. Anaplastic lymphoma kinase is required for neurogenesis in the developing central nervous system of zebrafish. PLoS ONE 8, e63757 (2013).
35. Lopes, S. S. et al. Leukocyte tyrosine kinase functions in pigment cell development. PLoS Genet. 4, e1000026 (2008).
36. Englund, C. et al. Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion. Nature 425, 512-516 (2003).
37. Lee, H. H., Norris, A., Weiss, J. B. & Frasch, M. Jelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers. Nature 425, 507-512 (2003).
38. Stute, C., Schimmelpfeng, K., Renkawitz-Pohl, R., Palmer, R. H. & Holz, A. Myoblast determination in the somatic and visceral mesoderm depends on Notch signalling as well as on milliways(miliAlk) as receptor for Jeb signalling. Development 131, 743-754 (2004).
39. Weiss, J. B., Suyama, K. L., Lee, H. H. & Scott, M. P. Jelly belly: a Drosophila LDL receptor repeat-containing signal required for mesoderm migration and differentiation. Cell 107, 387-398 (2001).
40. Ishihara, T. et al. HEN-1, a secretory protein with an LDL receptor motif, regulates sensory integration and learning in Caenorhabditis elegans. Cell 109, 639-649 (2002).
41. Bazigou, E. et al. Anterograde Jelly belly and Alk receptor tyrosine kinase signaling mediates retinal axon targeting in Drosophila. Cell 128, 961-975 (2007).
42. Rohrbough, J. & Broadie, K. Anterograde Jelly belly ligand to Alk receptor signaling at developing synapses is regulated by Mind the gap. Development 137, 3523-3533 (2010).
43. Gouzi, J. Y. et al. The receptor tyrosine kinase Alk controls neurofibromin functions in Drosophila growth and learning. PLoS Genet. 7, e1002281 (2011).
44. Cheng, L. Y. et al. Anaplastic lymphoma kinase spares organ growth during nutrient restriction in Drosophila. Cell 146, 435-447 (2011).
45. Inoue, T. & Thomas, J. H. Suppressors of transforming growth factor-beta pathway mutants in the Caenorhabditis elegans dauer formation pathway. Genetics 156, 1035-1046 (2000).
46. Shirinian, M., Varshney, G., Loren, C. E., Grabbe, C. & Palmer, R. H. Drosophila anaplastic lymphoma kinase regulates Dpp signalling in the developing embryonic gut. Differentiation 75, 418-426 (2007).
47. Kelsh, R. N. et al. Zebrafish pigmentation mutations and the processes of neural crest development. Development 123, 369-389 (1996).
48. Caren, H., Abel, F., Kogner, P. & Martinsson, T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem. J. 416, 153-159 (2008).
49. Chen, Y. et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455, 971-974 (2008).
50. George, R. E. et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455, 975-978 (2008).
51. Janoueix-Lerosey, I. et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 967-970 (2008).
52. Mosse, Y. P. et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455, 930-935 (2008). References 48-52 reported the identification of ALK mutations in both somatic and familial neuroblastoma.
53. Chand, D. et al. Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma. Dis. Model. Mech. 6, 373-382 (2013). A recent study of a number of ALK mutations observed in neuroblastoma that highlights three classes of ALK mutations: ligand-independent, ligand-dependent and kinase-dead mutations.
54. Schonherr, C. et al. Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684. Biochem. J. 440, 405-413 (2011).
55. Zhu, S. et al. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell 21, 362-373 (2012). One of the first articles describing an in vivo role for ALK-activating mutations with MYCN in tumour progression. The study was carried out in zebrafish.
56. Rodrigues, F. S., Yang, X., Nikaido, M., Liu, Q. & Kelsh, R. N. A simple, highly visual in vivo screen for anaplastic lymphoma kinase inhibitors. ACS Chem. Biol. 7, 1968-1974 (2012).
57. Lemmon, M. A. & Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 141, 1117-1134 (2010).
58. Armstrong, F. et al. Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells. Oncogene 23, 6071-6082 (2004). One of the few studies in which the properties of different ALK fusion proteins are compared.
59. Barreca, A. et al. Anaplastic lymphoma kinase (ALK) in human cancer. J. Mol. Endocrinol. 47, R11-R23 (2011).
60. Chiarle, R., Voena, C., Ambrogio, C., Piva, R. & Inghirami, G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nature Rev. Cancer 8, 11-23 (2008).
61. Ouyang, T. et al. Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA). J. Biol. Chem. 278, 30028-30036 (2003).
62. Bassermann, F. et al. NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry. Cell 122, 45-57 (2005).
63. Ambrogio, C. et al. The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. Cancer Res. 68, 8899-8907 (2008).
64. Colomba, A. et al. Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas. Oncogene 27, 2728-2736 (2008).
65. Ambrogio, C. et al. p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. Blood 106, 3907-3916 (2005).
66. Cussac, D. et al. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Blood 103, 1464-1471 (2004).
67. Voena, C. et al. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. Cancer Res. 67, 4278-4286 (2007).
68. Hegazy, S. A. et al. The tyrosine 343 residue of nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions. J. Biol. Chem. 285, 19813-19820 (2010).
69. Dupuis-Coronas, S. et al. The nucleophosmin-anaplastic lymphoma kinase oncogene interacts, activates, and uses the kinase PIKfyve to increase invasiveness. J. Biol. Chem. 286, 32105-32114 (2011).
70. Boccalatte, F. E. et al. The enzymatic activity of 5-aminoimidazole-4- carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL. Blood 113, 2776-2790 (2009).
71. Crockett, D. K., Lin, Z., Elenitoba-Johnson, K. S. & Lim, M. S. Identification of NPM-ALK interacting proteins by tandem mass spectrometry. Oncogene 23, 2617-2629 (2004).
72. Cussac, D. et al. Proteomic analysis of anaplastic lymphoma cell lines: identification of potential tumour markers. Proteomics 6, 3210-3222 (2006).
73. Galietta, A. et al. NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma. Blood 110, 2600-2609 (2007).
74. Lim, M. S. et al. The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways. Blood 114, 1585-1595 (2009).
75. Rush, J. et al. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nature Biotech. 23, 94-101 (2005).
76. Sjostrom, C. et al. Global proteome profiling of NPM/ALK-positive anaplastic large cell lymphoma. Exp. Hematol. 35, 1240-1248 (2007).
77. Wu, F., Wang, P., Young, L. C., Lai, R. & Li, L. Proteome-wide identification of novel binding partners to the oncogenic fusion gene protein, NPM-ALK, using tandem affinity purification and mass spectrometry. Am. J. Pathol. 174, 361-370 (2009).
78. Young, L. C. et al. Fusion tyrosine kinase NPM-ALK Deregulates MSH2 and suppresses DNA mismatch repair function novel insights into a potent oncoprotein. Am. J. Pathol. 179, 411-421 (2011).
79. Piva, R. et al. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J. Clin. Invest. 116, 3171-3182 (2006).
80. Schonherr, C. et al. Anaplastic lymphoma kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells. Oncogene 31, 5193-5200 (2012). This study was the first to report the regulation of MYCN by ALK in neuroblastoma cells.
81. Marzec, M. et al. Oncogenic kinase NPM/ALK induces expression of HIF1' mRNA. Oncogene 30, 1372-1378 (2011).
82. Pearson, J. D., Lee, J. K., Bacani, J. T., Lai, R. & Ingham, R. J. NPM-ALK and the JunB transcription factor regulate the expression of cytotoxic molecules in ALK-positive, anaplastic large cell lymphoma. Int. J. Clin. Exp. Pathol. 4, 124-133 (2011).
83. Staber, P. B. et al. The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. Blood 110, 3374-3383 (2007).
84. Dejean, E. et al. Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas. Leukemia 25, 1882-1890 (2011).
85. Desjobert, C. et al. MiR-29a downregulation in ALK-positive anaplastic large-cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression. Blood 117, 6627-6637 (2011).
86. Matsuyama, H. et al. miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma. Blood 118, 6881-6892 (2011).
87. Vishwamitra, D. et al. MicroRNA 96 is a post-transcriptional suppressor of anaplastic lymphoma kinase expression. Am. J. Pathol. 180, 1772-1780 (2012).
88. Ou, S. H., Bartlett, C. H., Mino-Kenudson, M., Cui, J. & Iafrate, A. J. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 17, 1351-1375 (2012).
89. Amin, H. M. & Lai, R. Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood 110, 2259-2267 (2007).
90. Stein, H. et al. CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 96, 3681-3695 (2000).
91. Swerdlow, S. H. et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed. Bosman, F. T.) (International Agency for Research on Cancer, 2008).
92. Cools, J. et al. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 34, 354-362 (2002).
93. Colleoni, G. W. et al. ATIC-ALK: a novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). Am. J. Pathol. 156, 781-789 (2000).
94. Ma, Z. et al. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood 95, 2144-2149 (2000).
95. Hernandez, L. et al. Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity. Am. J. Pathol. 160, 1487-1494 (2002).
96. Hernandez, L. et al. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood 94, 3265-3268 (1999).
97. Tort, F. et al. Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. Lab Invest. 81, 419-426 (2001).
98. Lamant, L., Dastugue, N., Pulford, K., Delsol, G. & Mariame, B. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2) (q25;p23) translocation. Blood 93, 3088-3095 (1999).
99. Meech, S. J. et al. Unusual childhood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin 4-anaplastic lymphoma kinase gene fusion. Blood 98, 1209-1216 (2001).
100. Siebert, R. et al. Complex variant translocation t(1;2) with TPM3-ALK fusion due to cryptic ALK gene rearrangement in anaplastic large-cell lymphoma. Blood 94, 3614-3617 (1999).
101. Lamant, L. et al. Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma. Genes Chromosomes Cancer 37, 427-432 (2003).
102. Touriol, C. et al. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 95, 3204-3207 (2000).
103. Griffin, C. A. et al. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res. 59, 2776-2780 (1999).
104. Lawrence, B. et al. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am. J. Pathol. 157, 377-384 (2000).
105. Bridge, J. A. et al. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am. J. Pathol. 159, 411-415 (2001).
106. Patel, A. S. et al. RANBP2 and CLTC are involved in ALK rearrangements in inflammatory myofibroblastic tumors. Cancer Genet. Cytogenet. 176, 107-114 (2007).
107. Debelenko, L. V. et al. Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor. Lab Invest. 83, 1255-1265 (2003).
108. Debiec-Rychter, M., Marynen, P., Hagemeijer, A. & Pauwels, P. ALK-ATIC fusion in urinary bladder inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 38, 187-190 (2003).
109. Panagopoulos, I. et al. Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor. Int. J. Cancer 118, 1181-1186 (2006).
110. Takeuchi, K. et al. Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification. Clin. Cancer Res. 17, 3341-3348 (2011).
111. Ma, Z. et al. Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 37, 98-105 (2003).
112. Chun, Y. S., Wang, L., Nascimento, A. G., Moir, C. R. & Rodeberg, D. A. Pediatric inflammatory myofibroblastic tumor: anaplastic lymphoma kinase (ALK) expression and prognosis. Pediatr. Blood Cancer 45, 796-801 (2005).
113. Falini, B. et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 93, 2697-2706 (1999).
114. Gascoyne, R. D. et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93, 3913-3921 (1999).
115. Savage, K. J. et al. ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 111, 5496-5504 (2008).
116. Shiota, M. et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood 86, 1954-1960 (1995).
117. Choung, H. S., Kim, H. J., Kim, W. S., Kim, K. & Kim, S. H. [Cytomorphology and molecular characterization of CLTC-ALK rearrangement in 2 cases of ALK-positive diffuse large B-cell lymphoma with extensive bone marrow involvement]. Kor. J. Lab Med. 28, 89-94 (2008) (in Korean).
118. Lee, H. W., Kim, K., Kim, W. & Ko, Y. H. ALK-positive diffuse large B-cell lymphoma: report of three cases. Hematol. Oncol. 26, 108-113 (2008).
119. Momose, S. et al. Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion. Hum. Pathol. 40, 75-82 (2009).
120. Reichard, K. K., McKenna, R. W. & Kroft, S. H. ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. Mod. Pathol. 20, 310-319 (2007).
121. Stachurski, D. et al. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma with a complex karyotype and cryptic 3' ALK gene insertion to chromosome 4 q22-24. Hum. Pathol. 38, 940-945 (2007).
122. De Paepe, P. et al. ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood 102, 2638-2641 (2003).
123. Adam, P. et al. A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2;5)(p23;q35) chromosome translocation. Am. J. Surg. Pathol. 27, 1473-1476 (2003).
124. Onciu, M. et al. ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. Blood 102, 2642-2644 (2003).
125. Takeuchi, K. et al. Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma. Haematologica 96, 464-467 (2011).
126. Van Roosbroeck, K. et al. ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions. Haematologica 95, 509-513 (2010).
127. Jemal, A. et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 101, 3-27 (2004).
128. Chaft, J. E. et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol. Cancer Ther. 11, 485-491 (2012).
129. Kris, M. G. et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI's Lung Cancer Mutation Consortium (LCMC). J. Clin Oncol 29, Abstr. CRA7506 (2011).
130. Rikova, K. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190-1203 (2007).
131. Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566 (2007).
132. Jung, Y. et al. Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing. Genes Chromosomes Cancer 51, 590-597 (2012).
133. Takeuchi, K. et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin. Cancer Res. 15, 3143-3149 (2009).
134. Togashi, Y. et al. KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS ONE 7, e31323 (2012).
135. Majewski, I. J. et al. Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J. Pathol. 230, 270-276 (2013).
136. Shaw, A. T. et al. Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls. J. Clin. Oncol. 29, Abstr. 7507 (2011). The most recent report of ongoing clinical trials looking at the effect of crizotinib compared with chemotherapy in ALK-positive lung cancer.
137. Camidge, D. R. et al. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J. Clin Oncol 29, Abstr. 2501 (2011).
138. Shaw, A. T. et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 27, 4247-4253 (2009).
139. Shaw, A. T. et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368, 2385-2394 (2013).
140. Debelenko, L. V. et al. Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. Mod. Pathol. 24, 430-442 (2011).
141. Sugawara, E. et al. Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method. Cancer 118, 4427-4436 (2012).
142. Sukov, W. R. et al. ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients. Mod. Pathol. 25, 1516-1525 (2012).
143. Lin, E. et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol. Cancer Res. 7, 1466-1476 (2009).
144. Lipson, D. et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nature Med. 18, 382-384 (2012).
145. Ren, H. et al. Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer. Cancer Res. 72, 3312-3323 (2012).
146. Du, X. L. et al. Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma. J. Mol. Med. 85, 863-875 (2007).
147. Jazii, F. R. et al. Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. World J. Gastroenterol. 12, 7104-7112 (2006).
148. Cessna, M. H. et al. Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases. Mod. Pathol. 15, 931-938 (2002).
149. Chiarle, R. et al. The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nature Med. 14, 676-680 (2008).
150. Dirks, W. G. et al. Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines. Int. J. Cancer 100, 49-56 (2002).
151. Lamant, L. et al. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am. J. Pathol. 156, 1711-1721 (2000).
152. Miyake, I. et al. Domain-specific function of ShcC docking protein in neuroblastoma cells. Oncogene 24, 3206-3215 (2005).
153. Miyake, I. et al. Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines. Oncogene 21, 5823-5834 (2002).
154. Passoni, L. et al. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res. 69, 7338-7346 (2009).
155. Salido, M. et al. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J. Thorac. Oncol. 6, 21-27 (2011).
156. De Brouwer, S. et al. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin. Cancer Res. 16, 4353-4362 (2010). This report describes ALK mutations and their frequency in a large cohort of patients with neuroblastoma.
157. Janoueix-Lerosey, I. et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J. Clin. Oncol. 27, 1026-1033 (2009).
158. Cazes, A. et al. Characterization of rearrangements involving the ALK gene reveals a novel truncated form associated with tumor aggressiveness in neuroblastoma. Cancer Res. 73, 195-204 (2013).
159. Choi, Y. L. et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363, 1734-1739 (2010). The first report of EML4-ALK resistance mutations in patients treated with crizotinib.
160. Murugan, A. K. & Xing, M. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res. 71, 4403-4411 (2011).
161. Okubo, J. et al. Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma. Oncogene 31, 4667-4676 (2012).
162. Wang, Y. W. et al. Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer. Neoplasia 13, 704-715 (2011).
163. Sasaki, T. et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res. 70, 10038-10043 (2010).
164. Maris, J. M., Hogarty, M. D., Bagatell, R. & Cohn, S. L. Neuroblastoma. Lancet 369, 2106-2120 (2007).
165. Martinsson, T. et al. Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy. Cancer Res. 71, 98-105 (2011). This reference reports the appearance of ALK mutation after treatment in a patient with neuroblastoma.
166. Schonherr, C. et al. The neuroblastoma ALK(I1250T) mutation is a kinase-dead RTK in vitro and in vivo. Transl. Oncol. 4, 258-265 (2011).
167. Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221 (2010).
168. Bresler, S. C. et al. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci. Transl. Med. 3, 108ra114 (2011).
169. Katayama, R. et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl. Med. 4, 120ra17 (2012). This reference reports mechanisms underlying crizotinib resistance in ALK-positive lung cancer.
170. Pugh, T. J. et al. The genetic landscape of high-risk neuroblastoma. Nature Genet. 45, 279-284 (2013). This report describes genetic aberrations, including ALK mutations, in a large cohort of patients with neuroblastoma.
171. Maris, J. M. Recent advances in neuroblastoma. N. Engl. J. Med. 362, 2202-2211 (2010).
172. Michels, E. et al. ArrayCGH-based classification of neuroblastoma into genomic subgroups. Genes Chromosomes Cancer 46, 1098-1108 (2007).
173. Vandesompele, J. et al. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J. Clin. Oncol. 23, 2280-2299 (2005).
174. Schulte, J. H. et al. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma. Clin. Cancer Res. 17, 5082-5092 (2011).
175. Brognard, J. & Hunter, T. Protein kinase signaling networks in cancer. Curr. Opin. Genet. Dev. 21, 4-11 (2011).
176. Porter, A. C. & Vaillancourt, R. R. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 17, 1343-1352 (1998).
177. Gustafson, W. C. & Weiss, W. A. Myc proteins as therapeutic targets. Oncogene 29, 1249-1259 (2010).
178. Chesler, L. et al. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res. 66, 8139-8146 (2006).
179. Liu, Z. & Thiele, C. J. ALK and MYCN: when two oncogenes are better than one. Cancer Cell 21, 325-326 (2012).
180. Berry, T. et al. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell 22, 117-130 (2012). One of the first articles describing an in vivo role for ALK-activating mutations with MYCN in neuroblastoma in mice.
181. Heukamp, L. C. et al. Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Sci. Transl. Med. 4, 141ra91 (2012).
182. Rasmuson, A. et al. Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma. PLoS ONE 7, e51297 (2012).
183. Holzel, M. et al. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 142, 218-229 (2010).
184. Rajagopalan, H., Nowak, M. A., Vogelstein, B. & Lengauer, C. The significance of unstable chromosomes in colorectal cancer. Nature Rev. Cancer 3, 695-701 (2003).
185. Vogelstein, B. & Kinzler, K. W. Cancer genes and the pathways they control. Nature Med. 10, 789-799 (2004).
186. Weickhardt, A. J. et al. Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. Cancer 119, 1467-1477 (2013).
187. Cataldo, V. D., Gibbons, D. L., Perez-Soler, R. & Quintas-Cardama, A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N. Engl. J. Med. 364, 947-955 (2011).
188. Hallberg, B. & Palmer, R. H. Crizotinib-latest champion in the cancer wars? N. Engl. J. Med. 363, 1760-1762 (2010).
189. Hallberg, B. & Palmer, R. H. ALK and NSCLC: Targeted therapy with ALK inhibitors. F1000 Med. Rep. 3, 21 (2011).
190. Al-Lazikani, B., Banerji, U. & Workman, P. Combinatorial drug therapy for cancer in the post-genomic era. Nature Biotech. 30, 679-692 (2012).
191. Bonvini, P., Gastaldi, T., Falini, B. & Rosolen, A. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK+ CD30+ lymphoma cells by the Hsp90 antagonist 17-allylamino, 17-demethoxygeldanamycin. Cancer Res. 62, 1559-1566 (2002).
192. Ge, J. et al. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J. Med. Chem. 49, 4606-4615 (2006).
193. Sydor, J. R. et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc. Natl Acad. Sci. USA 103, 17408-17413 (2006).
194. Normant, E. et al. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene 30, 2581-2586 (2011).
195. Sequist, L. V. et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J. Clin. Oncol. 28, 4953-4960 (2010).
196. Mosse, Y. P. et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 14, 472-480 (2013). A recent report on the use of crizotinib in paediatric ALK-positive cancer patients.
197. Yun, C. H. et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl Acad. Sci. USA 105, 2070-2075 (2008).
198. Sasaki, T. et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 71, 6051-6060 (2011).
199. Doebele, R. C. et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. 18, 1472-1482 (2012). This study reports molecular mechanisms of resistance to crizotinib in patients with ALK-positive NSCLC.
200. Bossi, R. T. et al. Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. Biochemistry 49, 6813-6825 (2010).
201. Lee, C. C. et al. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. Biochem. J. 430, 425-437 (2010). References 200 and 201 report the structure of the ALK kinase domain.
202. Azam, M., Latek, R. R. & Daley, G. Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112, 831-843 (2003).
203. Carpenter, E. L. & Mosse, Y. P. Targeting ALK in neuroblastoma- preclinical and clinical advancements. Nature Rev. Clin. Oncol. 9, 391-399 (2012).
204. Carpenter, E. L. et al. Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma. Oncogene 31, 4859-4867 (2012). This study reports a synergistic effect of inhibitory ALK antibodies when used with crizotinib on neuroblastoma cells.
205. Epstein, L. F., Chen, H., Emkey, R. & Whittington, D. A. The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase. J. Biol. Chem. 287, 37447-37457 (2012).
206. Tartari, C. J. et al. Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase. J. Biol. Chem. 283, 3743-3750 (2008).
207. Kornev, A. P. & Taylor, S. S. Defining the conserved internal architecture of a protein kinase. Biochim. Biophys. Acta 1804, 440-444 (2010).
208. Barouch-Bentov, R. et al. A conserved salt bridge in the G loop of multiple protein kinases is important for catalysis and for in vivo Lyn function. Mol. Cell 33, 43-52 (2009).
209. Morris, E. J. et al. E2F1 represses β-catenin transcription and is antagonized by both pRB and CDK8. Nature 455, 552-556 (2008).
210. Shen, L. L., Wang, Y. & Wang, D. Y. Involvement of genes required for synaptic function in aging control in C. elegans. Neurosci. Bull. 23, 21-29 (2007).
211. Chi, C. A. et al. Temperature and food mediate long-term thermotactic behavioral plasticity by association-independent mechanisms in C. elegans. J. Exp. Biol. 210, 4043-4052 (2007).
212. Kodama, E. et al. Insulin-like signaling and the neural circuit for integrative behavior in C. elegans. Genes Dev. 20, 2955-2960 (2006).
213. Shinkai, Y. et al. Behavioral choice between conflicting alternatives is regulated by a receptor guanylyl cyclase, GCY-28, and a receptor tyrosine kinase, SCD-2, in AIA interneurons of Caenorhabditis elegans. J. Neurosci. 31, 3007-3015 (2011).
214. Loren, C. E. et al. Identification and characterization of DAlk: a novel Drosophila melanogaster RTK which drives ERK activation in vivo. Genes Cells 6, 531-544 (2001).
215. Varshney, G. K. & Palmer, R. H. The bHLH transcription factor Hand is regulated by Alk in the Drosophila embryonic gut. Biochem. Biophys. Res. Commun. 351, 839-846 (2006).
216. Rohrbough, J., Kent, K. S., Broadie, K. & Weiss, J. B. Jelly Belly trans-synaptic signaling to anaplastic lymphoma kinase regulates neurotransmission strength and synapse architecture. Dev. Neurobiol. 73, 189-208 (2013).
217. Bourdeaut, F. et al. ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome. Eur. J. Hum. Genet. 20, 291-297 (2012).
218. McDuff, F. K., Lim, S. V., Dalbay, M. & Turner, S. D. Assessment of the transforming potential of novel anaplastic lymphoma kinase point mutants. Mol. Carcinog. 52, 79-83 (2013).
219. Heuckmann, J. M. et al. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin. Cancer Res. 17, 7394-7401 (2011).